More Articles

Economic evaluation of biosimilars Biosimilars/Research | Posted 25/11/2011

Biological drugs represent a fast-growing segment of the pharmaceutical market. They make up 32% of drugs in the development pipeline and 7.5% of marketed medicines and account for around 10% of ph...

FAIR Generics Act could remove 180-day exclusivity Policies & Legislation | Posted 25/11/2011

On 16 November 2011, US Senators Mr Jeff Bingaman, Mr David Vitter, Mr Sherrod Brown and Mr Jeff Merkley introduced a bill in the Senate that would remove the 180-day exclusivity period for generic...

Acino grabs Cephalon’s Middle East and African business Biosimilars/News | Posted 25/11/2011

Switzerland-based generics company Acino Pharma announced on 14 October 2011 that it had agreed to buy biopharmaceutical company Cephalon ’s combined Middle East and African business in a transacti...

Mylan poised to enter generic inhalers market Generics/News | Posted 25/11/2011

The global market for respiratory asthma and chronic obstructive pulmonary disorder (COPD) inhalers, a specialist field, is valued at more than US$34 billion (Euros 25.1 billion) and is averaging 7...

New Amgen Enbrel patent could block biosimilars until 2028 Biosimilars/News | Posted 25/11/2011

Amgen announced on 22 November 2011 that it had been granted a new US patent on its blockbuster drug Enbrel (etanercept).

Actavis launches generic valsartan in Europe Generics/News | Posted 25/11/2011

On 18 November 2011, Iceland-based generics company Actavis announced the launch of generic valsartan and valsartan HCT in nine European countries.

Biosimilars and cancer drug shortages in Europe Pharma News | Posted 18/11/2011

With all the talk about drug shortages in the US it might be easy to forget the rest of the world, but it seems that drug shortages are also hitting European countries and are affecting not just ge...

Bill to outlaw pay-to-delay moves ahead slowly Policies & Legislation | Posted 18/11/2011

A bill banning pay-to-delay, the practice by which originator and generics firms share the profit from drugs coming off patent rather than moving quickly to price reduction, is progressing slowly t...